Cytomegalovirus immunoglobulin serology prevalence in patients with newly diagnosed multiple myeloma treated within the GMMG-MM5 phase III trial.

Hans J SalwenderNiels WeinholdAxel BennerKaya MiahMaximilian MerzMathias HaenelChristian JehnElias MaiEkaterina MenisIgor BlauChristof ScheidDirk HoseAnja SeckingerSteffen LuntzBritta BesemerMarkus MunderPeter BrossartBertram GlassHans-Walter LindemannKatja WeiselChristine HanounPaul SchnitzlerSarah KlemmHartmut GoldschmidtMarc RaabAhmet Elmaagacli

Published in: Hematology (Amsterdam, Netherlands) (2024)

Younger patients with a positive CMV IgG/positive CMV IgM serology experienced a favorable effect on PFS, whereas a positive CMV IgG/positive CMV IgM serology at older age has a disadvantageous effect on PFS.

Keyphrases

phase iii
newly diagnosed
clinical trial
open label
multiple myeloma
phase ii
physical activity
epstein barr virus